IGMS

IGM Biosciences, Inc. (IGMS) | Rumor.io

IGM Biosciences

IGMS

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about IGMS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Jul 1

IGM Biosciences, Inc. ($IGMS) has entered into an agreement to be acquired by Concentra Biosciences for $1.247 per share, plus a contingent value right.
The acquisition has driven a significant increase in $IGMS stock price, with shares up 18% on high trading volume.
The deal is expected to close by August, with some investors expressing hope for a higher acquisition price.

Generated by AI

Sentiment

Of the messages about IGMS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +34.36
Bearish	—	—	—	0% -34.36

Bullish· Sep 17

$IGMS has shown a strong follow-through from its previous move, indicating a potential continuation of its uptrend.
The stock's short squeeze, with 36% of its float being shorted, could lead to a significant price increase, potentially reaching $30 or even $50.
$IGMS has already shown a strong gain of 11.06% in the last 20 minutes, with a significant increase in volume, suggesting that the stock is primed for further upside.

Bearish· Jan 10

IGM Biosciences, Inc. has halted development of two of its treatments and is exploring strategic alternatives to conserve cash.
The company has slashed its workforce by 73% and is left with a pipeline of no treatments, which could lead to a significant decline in value.
Analysts have downgraded their price targets for IGM Biosciences, with some predicting a potential drop of up to 90% in future value.

Generated by AI

Topics

Of the messages about IGMS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	99.24%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0.76%

Analysts· Mar 29

Analysts are discussing IGM Biosciences, Inc. (IGMS) in relation to its collaboration agreement with Sanofi for oncology, immunology, and inflammation targets.
Analysts are questioning whether IGM Biosciences, Inc. (IGMS) is a buy, following the announcement of its collaboration agreement with Sanofi.
Analysts at EF Hutton have initiated coverage of TC BioPharm (TCBP) with a "Buy" recommendation, which has been widely reported in the market.

Announcements· Jul 1

IGM Biosciences, Inc. (IGMS) has entered into an agreement to be acquired by Concentra Biosciences for $1.247 per share in cash, plus a contingent value right (CVR).
The acquisition is expected to close by August, with IGM Biosciences shares trading higher by 18% in response to the announcement.
The deal has a total value of $82.85 million, with Concentra Biosciences acquiring all outstanding shares of IGM Biosciences common stock.

Technical Analysis· Mar 29

IGMS has a clear long setup with a daily breakout and high volume, potentially indicating further upward movement.
The stock is holding up well and may gap up again, potentially filling the 45-50 range.
IGMS is in an uptrend, with the RSI indicator exiting the oversold zone, and is approaching a potential break over resistance at 33.

Generated by AI

Community

Of the messages about IGMS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	48.15%
Newcomers	100%	100%	100%	51.85%

Regulars· Jan 10

IGM Biosciences is halting development of two treatments and cutting its staff by 73% to conserve cash and explore strategic alternatives to maximize shareholder value.
The company's stock price has declined significantly, with a drop of 65.3% on January 10, 2025, and is currently trading at $2.15.
Analyst Brian Abrahams of RBC has downgraded IGM Biosciences' stock price target from $20 to $1.5, citing a decrease in potential downside change.

Newcomers· Jan 10

Newcomers are focusing on IGM Biosciences, Inc.'s (IGM) upcoming guidance at the JPM2025 event, anticipating a significant impact on the stock.
The $IGMS ticker is being discussed as a potential "stinker" of the day, indicating concerns about the company's performance.
IGM's cash burn is a major issue, with some users questioning the company's ability to contain it, specifically mentioning the loss of AATD.

Generated by AI

Also Discussed

Investors talking about IGMS also mention

#	Name	Attention
1	BCEL - Atreca, Inc.	——
2	Bicycle Therapeutics plc - ADRBCYC	0%0
3	Nkarta, Inc.NKTX	0%0
4	ETNB - 89bio, Inc.	——
5	ALLG - Allego N.V.	——
6	TSRI - TSR, Inc.	——
7	Jade Biosciences Inc.AVTE	0%0
8	AnaptysBio, Inc.ANAB	0%0
9	Zymeworks Inc.ZYME	0%0
10	MacroGenics Inc.MGNX	0%+0

IGM Biosciences, Inc.

Location

Social

What share of all stock conversation is about IGMS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Jul 1

IGM Biosciences, Inc. ($IGMS) has entered into an agreement to be acquired by Concentra Biosciences for $1.247 per share, plus a contingent value right.
The acquisition has driven a significant increase in $IGMS stock price, with shares up 18% on high trading volume.
The deal is expected to close by August, with some investors expressing hope for a higher acquisition price.

Generated by AI

Sentiment

Of the messages about IGMS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +34.36
Bearish	—	—	—	0% -34.36

Bullish· Sep 17

$IGMS has shown a strong follow-through from its previous move, indicating a potential continuation of its uptrend.
The stock's short squeeze, with 36% of its float being shorted, could lead to a significant price increase, potentially reaching $30 or even $50.
$IGMS has already shown a strong gain of 11.06% in the last 20 minutes, with a significant increase in volume, suggesting that the stock is primed for further upside.

Bearish· Jan 10

IGM Biosciences, Inc. has halted development of two of its treatments and is exploring strategic alternatives to conserve cash.
The company has slashed its workforce by 73% and is left with a pipeline of no treatments, which could lead to a significant decline in value.
Analysts have downgraded their price targets for IGM Biosciences, with some predicting a potential drop of up to 90% in future value.

Generated by AI

Topics

Of the messages about IGMS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	99.24%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0.76%

Analysts· Mar 29

Analysts are discussing IGM Biosciences, Inc. (IGMS) in relation to its collaboration agreement with Sanofi for oncology, immunology, and inflammation targets.
Analysts are questioning whether IGM Biosciences, Inc. (IGMS) is a buy, following the announcement of its collaboration agreement with Sanofi.
Analysts at EF Hutton have initiated coverage of TC BioPharm (TCBP) with a "Buy" recommendation, which has been widely reported in the market.

Announcements· Jul 1

IGM Biosciences, Inc. (IGMS) has entered into an agreement to be acquired by Concentra Biosciences for $1.247 per share in cash, plus a contingent value right (CVR).
The acquisition is expected to close by August, with IGM Biosciences shares trading higher by 18% in response to the announcement.
The deal has a total value of $82.85 million, with Concentra Biosciences acquiring all outstanding shares of IGM Biosciences common stock.

Technical Analysis· Mar 29

IGMS has a clear long setup with a daily breakout and high volume, potentially indicating further upward movement.
The stock is holding up well and may gap up again, potentially filling the 45-50 range.
IGMS is in an uptrend, with the RSI indicator exiting the oversold zone, and is approaching a potential break over resistance at 33.

Generated by AI

Community

Of the messages about IGMS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	48.15%
Newcomers	100%	100%	100%	51.85%

Regulars· Jan 10

IGM Biosciences is halting development of two treatments and cutting its staff by 73% to conserve cash and explore strategic alternatives to maximize shareholder value.
The company's stock price has declined significantly, with a drop of 65.3% on January 10, 2025, and is currently trading at $2.15.
Analyst Brian Abrahams of RBC has downgraded IGM Biosciences' stock price target from $20 to $1.5, citing a decrease in potential downside change.

Newcomers· Jan 10

Newcomers are focusing on IGM Biosciences, Inc.'s (IGM) upcoming guidance at the JPM2025 event, anticipating a significant impact on the stock.
The $IGMS ticker is being discussed as a potential "stinker" of the day, indicating concerns about the company's performance.
IGM's cash burn is a major issue, with some users questioning the company's ability to contain it, specifically mentioning the loss of AATD.

Generated by AI

IGM Biosciences

Social

Jul 1

Sentiment

Bullish· Sep 17

Bearish· Jan 10

Topics

Analysts· Mar 29

Announcements· Jul 1

Technical Analysis· Mar 29

Community

Regulars· Jan 10

Newcomers· Jan 10

Also Discussed

IGM Biosciences, Inc.

Company Information

Location

Also Discussed

Social

Jul 1

Sentiment

Bullish· Sep 17

Bearish· Jan 10

Topics

Analysts· Mar 29

Announcements· Jul 1

Technical Analysis· Mar 29

Community

Regulars· Jan 10

Newcomers· Jan 10